Regenxbio INC Schedule 13G passive stakes

JPMorgan Chase & Co. has filed a Schedule 13G, reporting beneficial ownership of 4.4% of REGENXBIO Inc.'s common stock as of May 29, 2026.

State Street Corporation has reported beneficial ownership of 5.3% of REGENXBIO Inc.'s common stock as of March 31, 2026.

The Vanguard Group reports 0% beneficial ownership in REGENXBIO Inc. following an internal realignment that disaggregated reporting responsibilities to its subsidiaries.

BlackRock Portfolio Management LLC has filed an amended Schedule 13G, reporting a 4.1% passive ownership stake in REGENXBIO INC as of December 31, 2025.

Redmile Group, LLC and its affiliates have reported a 9.9% beneficial ownership stake in REGENXBIO Inc., totaling 5,062,477 shares.

BlackRock Portfolio Management LLC has disclosed a 6.2% beneficial ownership stake in REGENXBIO INC, totaling 3,133,608 common shares, as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 7.3% of REGENXBIO INC.'s common stock as of March 31, 2025.

JPMorgan Chase & Co. has filed a Schedule 13G, reporting a 7.4% passive beneficial ownership in REGENXBIO Inc.'s common stock as of December 31, 2024.

State Street Corporation has disclosed a 4.4% beneficial ownership stake in REGENXBIO INC, holding 2,185,851 shares as of December 31, 2024, primarily through shared voting and dispositive power.

The Vanguard Group has filed an amended Schedule 13G, reporting a 6.02% beneficial ownership stake in REGENXBIO Inc. as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 11.0% of REGENXBIO Inc.'s Common Stock as of December 31, 2024.